Core Insights - International Medicine (000516.SZ) reported its Q3 2025 results on October 30, 2025, highlighting significant institutional investment activity [1] Institutional Holdings - As of October 29, 2025, six institutional investors disclosed holdings in International Medicine A-shares, totaling 754 million shares, which represents 33.67% of the company's total equity [1] - The institutional holding percentage increased by 0.45 percentage points compared to the previous quarter [1] Public Fund Activity - In this reporting period, 16 public funds were disclosed, including Jin Ying Theme Advantage Mixed, Huatai-PB Healthcare A, Guotai Rongan Multi-Strategy Flexible Allocation Mixed A, Penghua Healthcare Stocks, and Penghua Pension Industry Stocks [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings, contributing an increase of 0.52% compared to the previous period [1]

Core Viewpoint - The AI Fund Penghua Pension Industry Stock (000854) reported a profit of 84.99 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.4241 yuan. The fund's net value growth rate was 21.38%, and the fund size reached 464 million yuan by the end of the reporting period [3][36]. Fund Performance - As of September 2, the fund's unit net value was 2.983 yuan. The fund manager, Jin Xiaofei, has managed six funds, all of which have shown positive returns over the past year. The highest growth rate among these funds was 112.81% for Penghua Medical Technology Stock A, while the lowest was 42.01% for Penghua Innovative Medicine Mixed A [3]. - The fund's performance over different time frames includes a three-month net value growth rate of 23.11% (ranked 66 out of 167), a six-month growth rate of 38.49% (ranked 14 out of 167), a one-year growth rate of 56.67% (ranked 49 out of 166), and a three-year growth rate of -2.20% (ranked 113 out of 160) [6]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately -1038.47 times, compared to the industry average of 23.39 times. The weighted average price-to-book (P/B) ratio was about 4.71 times, while the industry average was 2.44 times. The weighted average price-to-sales (P/S) ratio was 9.47 times, against an industry average of 2.1 times [13]. Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.11%, and the weighted average net profit growth rate was -0.83%. The weighted annualized return on equity was 0% [22]. Risk and Return Metrics - The fund's Sharpe ratio over the past three years was -0.2327, ranking 133 out of 159 comparable funds. The maximum drawdown over the same period was 44.66%, with the largest single-quarter drawdown occurring in Q1 2021 at 25.48% [30][32]. - The fund's average stock position over the past three years was 84.94%, compared to the industry average of 88.01% [35]. Fundholder Composition - As of June 30, 2025, the fund had 56,200 holders, collectively holding 193 million shares. Management and staff held 133,800 shares (0.07%), institutional investors held 0.02%, and individual investors accounted for 99.98% of the holdings [40]. Trading Activity - The fund's turnover rate for the last six months was approximately 64.05%, which has consistently been below the industry average [43]. Top Holdings - As of June 30, 2025, the fund's top ten holdings included companies such as Baijia Shenzhou, Heng Rui Pharmaceutical, Dize Pharmaceutical, Shouyao Holdings, Aosaikang, Ganli Pharmaceutical, Nuocheng Jianhua, Zhixiang Jintai, Bai'ao Tai, and Kexing Pharmaceutical [46].

Core Viewpoint - The AI Fund Penghua Pension Industry Stock (000854) reported a profit of 41.95 million yuan for Q2 2025, with a weighted average profit per fund share of 0.2136 yuan, and a net value growth rate of 9.71% during the reporting period [3]. Fund Performance - As of July 17, the fund's unit net value was 2.716 yuan, with a fund size of 464 million yuan [3][16]. - The fund's performance over different time frames includes a 23.34% growth rate over the last three months, ranking 12 out of 167 comparable funds; a 38.93% growth rate over the last six months, ranking 2 out of 167; a 35.39% growth rate over the last year, ranking 30 out of 166; and a -14.91% growth rate over the last three years, ranking 100 out of 159 [4]. Investment Strategy - The fund manager indicated a strong focus on innovative pharmaceuticals since the end of 2022, maintaining a high position despite market fluctuations, which contributed to significant gains in this sector [3]. - The average stock position over the last three years was 84.94%, compared to the industry average of 87.96%, with the highest position reaching 94.75% in Q1 2019 and the lowest at 73.24% in Q3 2021 [15]. Risk Metrics - The fund's Sharpe ratio over the last three years was -0.2327, ranking 133 out of 159 comparable funds [10]. - The maximum drawdown over the last three years was 44.66%, with the largest single-quarter drawdown occurring in Q1 2021 at 25.48% [12]. Top Holdings - As of Q2 2025, the fund's top ten holdings included companies such as BeiGene, Hengrui Medicine, and Dizhihua Pharmaceutical, among others [19].